Company Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
149.4 USD -3.20% Intraday chart for Alnylam Pharmaceuticals, Inc. +1.93% -21.92%

Business Summary

Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Number of employees: 2,100

Sales per Business

USD in Million2022Weight2023Weight Delta
Ribonucleic Acid Interference Therapeutics
100.0 %
1,037 100.0 % 1,828 100.0 % +76.23%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
69.8 %
616 59.4 % 1,276 69.8 % +107.21%
Europe
21.8 %
315 30.4 % 399 21.8 % +26.83%
Rest of the World
8.4 %
107 10.3 % 153 8.4 % +43.31%

Managers

Managers TitleAgeSince
Chief Executive Officer 61 16-09-18
Director of Finance/CFO 56 19-08-12
Compliance Officer - 22-09-20
Chief Tech/Sci/R&D Officer - 17-07-31
Chief Tech/Sci/R&D Officer 56 04-12-31
Chief Tech/Sci/R&D Officer - 15-09-30
Chief Tech/Sci/R&D Officer 56 14-10-28
Public Communications Contact - 21-01-31
Investor Relations Contact 43 15-08-31
Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Director/Board Member 70 15-12-17
Director/Board Member 72 22-08-21
Director/Board Member 68 19-01-09
Chairman 63 14-06-30
Founder 79 02-06-13
Director/Board Member 68 23-03-06
Director/Board Member 65 14-12-16
Director/Board Member 78 12-04-22
Director/Board Member 64 18-05-31
Chief Executive Officer 61 16-09-18

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 125,945,793 125,446,997 ( 99.60 %) 0 99.60 %

Shareholders

NameEquities%Valuation
Capital Research & Management Co. (World Investors)
12.84 %
16,174,563 12.84 % 2 444 M $
Vanguard Fiduciary Trust Co.
9.483 %
11,943,895 9.483 % 1 805 M $
Fidelity Management & Research Co. LLC
8.187 %
10,311,480 8.187 % 1 558 M $
Wellington Management Co. LLP
5.728 %
7,214,198 5.728 % 1 090 M $
BlackRock Advisors LLC
5.640 %
7,103,658 5.640 % 1 073 M $
Baillie Gifford & Co.
5.532 %
6,967,097 5.532 % 1 053 M $
Dodge & Cox
2.917 %
3,674,310 2.917 % 555 M $
Capital Research & Management Co. (International Investors)
2.848 %
3,586,657 2.848 % 542 M $
T. Rowe Price International Ltd.
2.766 %
3,483,969 2.766 % 526 M $
T. Rowe Price Investment Management, Inc.
2.720 %
3,426,063 2.720 % 518 M $

Company contact information

Alnylam Pharmaceuticals, Inc.

675 West Kendall Street Henri A. Termeer Square

02142, Cambridge

+617 551 8200

http://www.alnylam.com
address Alnylam Pharmaceuticals, Inc.(ALNY)